Milestone Pharmaceuticals Inc 's (MIST) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 
Milestone Pharmaceuticals Inc   (NASDAQ: MIST)
 



  Milestone Pharmaceuticals Inc Outlook

On May 13 2024 the Milestone Pharmaceuticals Inc provided following guidance

Milestone Pharmaceuticals Inc. announced its financial results for the first quarter of 2024 and provided an update on regulatory and corporate developments. The company resubmitted the New Drug Application (NDA) for etripamil in paroxysmal supraventricular tachycardia (PSVT) in the first quarter of 2024. Additionally, Milestone Pharmaceuticals reported that its cash resources as of March 31, 2024 are expected to support operations until 2026.

Furthermore, the company is currently in discussions with the Food and Drug Administration (FDA) to finalize the Phase 3 protocol for etripamil in atrial fibrillation with rapid ventricular response (AFib-RVR). This progress indicates a positive step forward in the development and potential approval of etripamil for this indication.

Overall, Milestone Pharmaceuticals Inc. continues to make strides in advancing its pipeline of innovative therapies for cardiovascular conditions, positioning itself for future success in the pharmaceutical industry.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.